Is Danaher Corporation (DHR) a risky stock?
As of July 21, 2026, Clavix grades Danaher Corporation (DHR) A- for risk, a composite score of 80 out of 100 on an A+ to F scale, which puts DHR in the "solid" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 21, 2026. Clavix regrades every trading day.
The five risk dimensions behind DHR's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how DHR scores on each, as of July 21, 2026.
What's moving DHR's risk right now
Company-specific signals Clavix flags behind DHR's current grade, drawn from recent news and filings as of July 21, 2026.
Danaher is buying StatLab Medical Products to grow its diagnostics arm and add recurring consumables revenue. The company is also working through its Masimo integration while carrying higher debt and rising input costs.
Watershed Asset Management opened a $1.78 million position in Danaher during Q1, while Wealthfront Advisers cut its holdings by 17.6% in the same period. The opposite moves point to divided institutional news signal with no clear signal.
What a A- grade means
On the Clavix A+ to F scale, DHR's composite of 80 falls in the B band (65–79), read as "solid." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell DHR or any security. Grades are risk indicators, not predictions of return. Data may be delayed.